Literature DB >> 7571717

Small intestinal sulphoxidation of albendazole.

C Villaverde1, A I Alvarez, P Redondo, J Voces, J L Del Estal, J G Prieto.   

Abstract

1. The in vitro sulphoxidation of Albendazole (ABZ) by rat intestinal microsomes has been examined. The results revealed intestinal sulphoxidation of ABZ by intestinal microsomes in a NADPH-dependent enzymatic system. The kinetic constants for sulphoxidase activity were Vmax = 46 pmol/min/mg protein and Michaelis constant Km = 6.8 microM. 2. The possible effect of inducers (Arochlor 1254 and ABZ pretreatment) and inhibitors (erythromycin, methimazole, carbon monoxide and fenbendazole), was also studied. In rat pretreated with Arochlor 1254, Vmax was 52 pmol/min/mg protein, whereas oral administration of ABZ increased the intestinal sulphoxidation of the drug, Vmax being 103 pmol/min/mg protein. 3. Erythromycin did not change the enzymatic bioconversion of ABZ, but methimazole and carbon monoxide inhibited the enzyme activity by approximately 60 and 30% respectively. Fenbendazole (a structural analogue of ABZ) was a competitive inhibitor of the sulphoxidation process, characterized by a Ki or 69 microM. 4. These data demonstrate that the intestinal enzymes contributing to the initial sulphoxidation of ABZ may be similar to the hepatic enzymes involved in the biotransformation process by the P450 and FMO systems, a conclusion that needs to be further established.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571717     DOI: 10.3109/00498259509061863

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

Authors:  Natascia Corti; Antje Heck; Katharina Rentsch; Walter Zingg; Alexander Jetter; Bruno Stieger; Christiane Pauli-Magnus
Journal:  Eur J Clin Pharmacol       Date:  2009-06-27       Impact factor: 2.953

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

3.  Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep.

Authors:  B P Capece; G Castells; F Pérez; M Arboix; C Cristòfol
Journal:  Vet Res Commun       Date:  2000-07       Impact factor: 2.459

Review 4.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

5.  Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.

Authors:  Sabine U Vorrink; Yitian Zhou; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  Toxicol Sci       Date:  2018-06-01       Impact factor: 4.849

6.  Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers.

Authors:  Laura Ceballos; Alejandro Krolewiecki; Marisa Juárez; Laura Moreno; Fabian Schaer; Luis I Alvarez; Rubén Cimino; Judd Walson; Carlos E Lanusse
Journal:  PLoS Negl Trop Dis       Date:  2018-01-18

Review 7.  The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development.

Authors:  Paul A Walker; Stephanie Ryder; Andrea Lavado; Clive Dilworth; Robert J Riley
Journal:  Arch Toxicol       Date:  2020-05-06       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.